MNKD NASDAQ
MannKind Corporation
1W: +13.8%
1M: -5.9%
3M: -11.0%
YTD: -32.1%
1Y: -29.4%
3Y: -7.3%
5Y: -18.8%
$3.80
-0.15 (-3.80%)
Weekly Expected Move ±10.3%
$3
$3
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.18
Neutral
2 bullish
0 neutral
3 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (100)
Liquidia plunges after court ruling in United Therapeutics patent fight (update)
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus
Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan
MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - directorstalkinterviews.com
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses
MannKind (MNKD) Stock May Be 15% Undervalued After Inhaled GLP 1 Deal - simplywall.st
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching
MannKind, Rose Pharma team up for inhaled GLP-1 therapy
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Bank of New York Mellon Corp Buys New Stake in MannKind Corporation $MNKD
MannKind to Present at Upcoming Investor Conferences
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative - Yahoo Finance
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
MannKind Corporation (NASDAQ:MNKD) Receives Average Recommendation of “Moderate Buy” from Analysts
Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD
MannKind (MNKD) Stock Faces Margin Strain Despite Stronger Product Sales - simplywall.st
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ...
MannKind Q2 Earnings Call Highlights
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings Week Ahead: PLTR, AMD, PFE, DIS, SHOP, VTRS, CGC, MCD, ROKU, ABNB, and more
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy?
MannKind (MNKD) Following Furoscix Approval, Buying Opportunity Or Already Priced In?
MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks
How Investors May Respond To MannKind (MNKD) Winning FDA Approval For At‑Home Furoscix Autoinjector
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits
MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds - Yahoo Finance
MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing - Yahoo Finance
What This MannKind Filing Reveals About Three Years of Underperformance
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?
MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval
$MNKD stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
MNKD: Ready? Set? Mankind. - Moomoo
Is MannKind Corporation (MNKD) A Good Stock To Buy Now?
Is MannKind Corporation (MNKD) A Good Stock To Buy Now?
Is MannKind Corporation (MNKD) A Good Stock To Buy Now? - Yahoo Finance
MannKind Corp (MNKD) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
MannKind (MNKD) Secures Pediatric Afrezza Grant, Is The Stock Still Cheap? - simplywall.st
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
MannKind (MNKD) Stock After Afrezza Pediatric Approval And New Diabetes Data How Does The Valuation Stack Up - simplywall.st
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” - Yahoo Finance
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance
Jim Cramer Says He Blessed MannKind as a Speculation Only
Jim Cramer Says He Blessed MannKind as a Speculation Only - Yahoo Finance
Is MannKind (MNKD) Now An Opportunity After A 39% Year To Date Share Price Decline? - simplywall.st
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
Inhaled insulin data explore options for kids, pregnancy and pump users - Stock Titan
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial Relief - Has The Bull Case Changed?
$MNKD stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind gains FDA nod to expand inhaled insulin for children
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MannKind to Present at Jefferies Global Healthcare Conference
MannKind to Present at Jefferies Global Healthcare Conference
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M - Yahoo Finance
ARKO Petroleum And 2 Other Value Stocks Priced Below Estimated Worth
Wells Fargo Raises its Price Target on MannKind (MNKD) to $10
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets - Yahoo Finance
MannKind targets $110M-$120M 2026 FUROSCIX revenue as it nears May 29 and July 26 PDUFA catalysts
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
MannKind drops after Q1 miss